These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 19480561

  • 1. Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.
    Coyne CP, Ross MK, Bailey JG.
    J Drug Target; 2009 Jul; 17(6):474-89. PubMed ID: 19480561
    [Abstract] [Full Text] [Related]

  • 2. Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.
    Coyne CP, Jones T, Bear R.
    Cancer Biother Radiopharm; 2012 Feb; 27(1):41-55. PubMed ID: 22191802
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma.
    Coyne CP, Jones T, Pharr T.
    Bioorg Med Chem; 2011 Jan 01; 19(1):67-76. PubMed ID: 21169024
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.
    Coyne CP, Jones T, Bear R.
    J Cancer Res Ther Oncol; 2014 Apr 09; 2(1):. PubMed ID: 25844392
    [Abstract] [Full Text] [Related]

  • 7. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
    Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES, Paulsen KD.
    Cancer Res; 2005 Jul 15; 65(14):6371-9. PubMed ID: 16024640
    [Abstract] [Full Text] [Related]

  • 8. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
    Cornelissen B, Kersemans V, McLarty K, Tran L, Reilly RM.
    Cancer Biother Radiopharm; 2009 Apr 15; 24(2):163-73. PubMed ID: 19409037
    [Abstract] [Full Text] [Related]

  • 9. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y, Noy R, Wels WS, Benhar I.
    Cancer Lett; 2007 Nov 08; 257(1):124-35. PubMed ID: 17698286
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.
    Coyne CP, Jones T, Bear R.
    J Cancer Ther; 2015 Jan 08; 6(1):62-89. PubMed ID: 25821636
    [Abstract] [Full Text] [Related]

  • 11. Chemical conjugation of a novel antibody-interleukin 2 immunoconjugate against c-erbB-2 product.
    Li J, Lee SE, Belciug M, Ring DB, Kwok CS.
    Chin Med J (Engl); 2000 Feb 08; 113(2):151-3. PubMed ID: 11775541
    [Abstract] [Full Text] [Related]

  • 12. Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent.
    Blend MJ, Stastny JJ, Swanson SM, Brechbiel MW.
    Cancer Biother Radiopharm; 2003 Jun 08; 18(3):355-63. PubMed ID: 12954122
    [Abstract] [Full Text] [Related]

  • 13. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.
    Mandler R, Wu C, Sausville EA, Roettinger AJ, Newman DJ, Ho DK, King CR, Yang D, Lippman ME, Landolfi NF, Dadachova E, Brechbiel MW, Waldmann TA.
    J Natl Cancer Inst; 2000 Oct 04; 92(19):1573-81. PubMed ID: 11018093
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
    Featherstone JM, Lwaleed BA, Speers AG, Hayes MC, Birch BR, Cooper AJ.
    Urology; 2009 Aug 04; 74(2):378-84. PubMed ID: 19501884
    [Abstract] [Full Text] [Related]

  • 16. Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.
    Coyne CP, Jones T, Bear R.
    J Clin Exp Oncol; 2013 Aug 04; 2(2):. PubMed ID: 26251840
    [Abstract] [Full Text] [Related]

  • 17. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.
    Clin Cancer Res; 2009 Jul 15; 15(14):4612-21. PubMed ID: 19584156
    [Abstract] [Full Text] [Related]

  • 18. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG.
    Cancer Res; 2009 Dec 01; 69(23):8987-95. PubMed ID: 19934334
    [Abstract] [Full Text] [Related]

  • 19. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
    Ding H, Helguera G, Rodríguez JA, Markman J, Luria-Pérez R, Gangalum P, Portilla-Arias J, Inoue S, Daniels-Wells TR, Black K, Holler E, Penichet ML, Ljubimova JY.
    J Control Release; 2013 Nov 10; 171(3):322-9. PubMed ID: 23770212
    [Abstract] [Full Text] [Related]

  • 20. Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).
    Coyne CP, Jones T, Bear R.
    Med Chem (Los Angeles); 2013 May 10; 3(2):210-223. PubMed ID: 26225219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.